Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126961501 | 12696150 | 1 | I | 20150128 | 20160829 | 20160829 | EXP | JP-ELI_LILLY_AND_COMPANY-JP201501010280 | ELI LILLY AND CO | 85.00 | YR | F | Y | 0.00000 | 20160824 | CN | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 126961501 | 12696150 | 1 | PS | FORTEO | TERIPARATIDE | 1 | Subcutaneous | UNK | U | U | C316372C | 21318 | INJECTION | ||||||
| 126961501 | 12696150 | 2 | C | ONEALFA | ALFACALCIDOL | 1 | Oral | UNK | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 126961501 | 12696150 | 1 | Product used for unknown indication |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 126961501 | 12696150 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 126961501 | 12696150 | Anaemia | |
| 126961501 | 12696150 | Blood calcium increased | |
| 126961501 | 12696150 | Injection site bruising | |
| 126961501 | 12696150 | Muscle spasms | |
| 126961501 | 12696150 | Nail growth abnormal | |
| 126961501 | 12696150 | Nephrolithiasis |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 126961501 | 12696150 | 1 | 20141217 | 0 |